Dyshidrotic dermatitis characteristically follows a relapsing-remitting course and so will most often resolve without any treatment, however, patients will appreciate therapies to lessen the duration and prevent recurrence of uncomfortable eruptions.
Lifestyle measures
Advise patients to avoid identified triggers or exacerbating factors. Provide all patients with strategies to maintain effective skin barrier mechanisms such as frequent use of emollients, avoidance of irritants, and use of protective gloves or footwear.[23]Warshaw E. Therapeutic options for chronic hand dermatitis. Dermatol Ther. 2004;17:240-250.
http://www.ncbi.nlm.nih.gov/pubmed/15186370?tool=bestpractice.com
Advise against prolonged wet work and harsh cleansers, and suggest immediately moisturizing with a heavy emollient, preferably a white soft paraffin-based product, after each exposure to water.[23]Warshaw E. Therapeutic options for chronic hand dermatitis. Dermatol Ther. 2004;17:240-250.
http://www.ncbi.nlm.nih.gov/pubmed/15186370?tool=bestpractice.com
In addition to these measures, some patients require further adjunctive therapies:
Pruritus
Hyperhidrosis
Hyperhidrosis is an exacerbating factor for some patients with dyshidrotic dermatitis.
In this subset of patients, modalities that interrupt eccrine sweat function, such as topical chloride, iontophoresis, topical glycopyrronium and onabotulinumtoxinA (botulinum toxin type A), may be helpful.[24]Swartling C, Naver H, Lindberg M, et al. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2002;47:667-671.
http://www.ncbi.nlm.nih.gov/pubmed/12399757?tool=bestpractice.com
[25]Odia S, Vocks E, Rakoski J, et al. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol. 1996;76:472-474.
http://www.ncbi.nlm.nih.gov/pubmed/8982415?tool=bestpractice.com
[26]Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002;16:40-42.
http://www.ncbi.nlm.nih.gov/pubmed/11952288?tool=bestpractice.com
These treatments are relatively safe, although an adverse effect of onabotulinumtoxinA is temporary hand weakness.
OnabotulinumtoxinA is preferred over iontophoresis.
Nickel allergies
Several studies suggest a systemic role for nickel-related exacerbation of dyshidrotic dermatitis in nickel-allergic patients.[27]Veien NK, Kaaber K. Nickel, cobalt and chromium sensitivity in patients with pompholyx (dyshidrotic eczema). Contact Dermatitis. 1979;5:371-374.
http://www.ncbi.nlm.nih.gov/pubmed/160856?tool=bestpractice.com
[28]Veien NK, Hattel T, Justesen O, et al. Dietary restrictions in the treatment of adult patients with eczema. Contact Dermatitis. 1987;17:223-228.
http://www.ncbi.nlm.nih.gov/pubmed/3427949?tool=bestpractice.com
After nickel-sensitive patients are identified through patch testing or oral challenge, they should stringently avoid contact with all nickel-containing objects. A dimethylglyoxime kit is used to test frequently encountered objects for nickel content.
If after these precautions the patient is still experiencing flares, some authors recommend attempting to decrease systemic nickel exposure.[28]Veien NK, Hattel T, Justesen O, et al. Dietary restrictions in the treatment of adult patients with eczema. Contact Dermatitis. 1987;17:223-228.
http://www.ncbi.nlm.nih.gov/pubmed/3427949?tool=bestpractice.com
[29]Veien NK, Hattel T, Justesen O, et al. Dietary treatment of nickel dermatitis. Acta Derm Venereol. 1985;65:138-142.
http://www.ncbi.nlm.nih.gov/pubmed/2408416?tool=bestpractice.com
A diet low in nickel is useful in some motivated patients with stubborn dyshidrotic dermatitis and a nickel allergy proven via patch-test or oral challenge.[28]Veien NK, Hattel T, Justesen O, et al. Dietary restrictions in the treatment of adult patients with eczema. Contact Dermatitis. 1987;17:223-228.
http://www.ncbi.nlm.nih.gov/pubmed/3427949?tool=bestpractice.com
[29]Veien NK, Hattel T, Justesen O, et al. Dietary treatment of nickel dermatitis. Acta Derm Venereol. 1985;65:138-142.
http://www.ncbi.nlm.nih.gov/pubmed/2408416?tool=bestpractice.com
Other methods employed for decreasing the systemic effects of nickel are treatment with oral agents (such as vitamin C, iron, disulfiram and cromolyn sodium) and hyposensitization.[30]Kaaber K, Menné T, Veien N, et al. Treatment of nickel dermatitis with Antabuse; a double blind study. Contact Dermatitis. 1983;9:297-299.
http://www.ncbi.nlm.nih.gov/pubmed/6352169?tool=bestpractice.com
[31]Pigatto PD, Gibelli E, Fumagalli M, et al. Disodium cromoglycate versus diet in the treatment and prevention of nickel-positive pompholyx. Contact Dermatitis. 1990;22:27-31.
http://www.ncbi.nlm.nih.gov/pubmed/2138953?tool=bestpractice.com
[32]Santucci B, Cristaudo A, Cannistraci C, et al. Nickel sensitivity: effects of prolonged oral intake of the element. Contact Dermatitis. 1988;19:202-205.
http://www.ncbi.nlm.nih.gov/pubmed/3191682?tool=bestpractice.com
A metabolite of disulfiram binds divalent metals, including nickel, while cromolyn sodium inhibits mast cell degranulation. Iron deficiency anemia is understood to enhance nickel absorption (secondary to upregulation of divalent metal transporter 1 [DMT1] on enterocyte luminal surfaces) and is treated with iron supplementation. Vitamin C acts to suppress nickel absorption.[33]Sharma AD. Low nickel diet in dermatology. Indian J Dermatol. 2013 May;58(3):240.
https://www.e-ijd.org/article.asp?issn=0019-5154;year=2013;volume=58;issue=3;spage=240;epage=240;aulast=Sharma
http://www.ncbi.nlm.nih.gov/pubmed/23723488?tool=bestpractice.com
However, nickel-directed therapies, as a whole lack large, randomized, controlled studies.
Patients unresponsive to lifestyle measures
If the condition persists after conservative lifestyle measures are taken, topical corticosteroids are frequently used.[15]Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020 Jan;34 Suppl 1:13-21.
https://onlinelibrary.wiley.com/doi/10.1111/jdv.16062
http://www.ncbi.nlm.nih.gov/pubmed/31860736?tool=bestpractice.com
[34]Veien NK, Olhom Larsen P, Thestrup-Pedersen K, et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140:882-886.
http://www.ncbi.nlm.nih.gov/pubmed/10354026?tool=bestpractice.com
[35]Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol. 1992;72(1):69-71.
http://www.ncbi.nlm.nih.gov/pubmed/1350154?tool=bestpractice.com
A potent preparation may be needed for the first couple of weeks to gain control of the eruption. This is then tapered to a less-potent formulation for the remainder of the treatment course.[36]Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023 Jul;89(1):e1-20.
https://www.jaad.org/article/S0190-9622(23)00004-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/36641009?tool=bestpractice.com
Topical immunomodulators, such as tacrolimus and pimecrolimus, are helpful corticosteroid-sparing agents for long-term maintenance and when there are concerns about skin atrophy with topical corticosteroids.[15]Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020 Jan;34 Suppl 1:13-21.
https://onlinelibrary.wiley.com/doi/10.1111/jdv.16062
http://www.ncbi.nlm.nih.gov/pubmed/31860736?tool=bestpractice.com
[37]Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK 506) and mometasone furoate in the treatment of dyshidrotic palmar eczema: A randomized, observer-blinded trial. J Am Acad Dermatol. 2002;46:73-77.
http://www.ncbi.nlm.nih.gov/pubmed/11756949?tool=bestpractice.com
[38]Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004;73:31-38.
http://www.ncbi.nlm.nih.gov/pubmed/14964629?tool=bestpractice.com
[39]Christoffers WA, Coenraads PJ, Svensson Å, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019 Apr 26;4(4):CD004055.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004055.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/31025714?tool=bestpractice.com
However, topical immunomodulators do not penetrate thick skin well, so if these agents are used on thickly keratinized skin, a keratolytic (such as a cream containing urea) can be coadministered to improve absorption.[37]Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK 506) and mometasone furoate in the treatment of dyshidrotic palmar eczema: A randomized, observer-blinded trial. J Am Acad Dermatol. 2002;46:73-77.
http://www.ncbi.nlm.nih.gov/pubmed/11756949?tool=bestpractice.com
[38]Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004;73:31-38.
http://www.ncbi.nlm.nih.gov/pubmed/14964629?tool=bestpractice.com
Lifestyle measures may need to be continued in selected patients, despite escalation of therapy.
Patients unresponsive to topical therapies
A short course of oral prednisone is sometimes helpful if patients' symptoms have severely flared and cannot be controlled with skin-directed methods.[2]Fowler JF Jr, Storrs FJ. Nickel allergy and dyshidrotic eczema: are they related? Am J Contact Dermatol. 2001;12:119-121.
http://www.ncbi.nlm.nih.gov/pubmed/11381350?tool=bestpractice.com
Long-term use of oral corticosteroids is discouraged because of the well-known range of adverse effects. Topical corticosteroids and lifestyle measures are continued if necessary.
Recalcitrant disease
Patients at this level of severity should seek consultation with a dermatology specialist. Phototherapy or immunosuppressants may be considered. Topical psoralen (e.g., methoxsalen) plus ultraviolet A (PUVA) and narrowband UVB are effective measures.[15]Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020 Jan;34 Suppl 1:13-21.
https://onlinelibrary.wiley.com/doi/10.1111/jdv.16062
http://www.ncbi.nlm.nih.gov/pubmed/31860736?tool=bestpractice.com
[39]Christoffers WA, Coenraads PJ, Svensson Å, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019 Apr 26;4(4):CD004055.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004055.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/31025714?tool=bestpractice.com
[40]Davis MD, McEvoy M, el-Azhary RA. Topical psoralen-ultraviolet A therapy for palmoplantar dermatoses: experience with 35 consecutive patients. Mayo Clin Proc. 1998;73:407-411.
http://www.ncbi.nlm.nih.gov/pubmed/9581579?tool=bestpractice.com
[41]Schempp CM, Müller H, Czech W, et al. Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. J Am Acad Dermatol. 1997;36:733-737.
http://www.ncbi.nlm.nih.gov/pubmed/9146535?tool=bestpractice.com
[42]Behrens S, von Kobyletzki G, Gruss C, et al. PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. Photodermatol Photoimmunol Photomed. 1999;15:47-51.
http://www.ncbi.nlm.nih.gov/pubmed/10321515?tool=bestpractice.com
Oral PUVA is a second-line option as, while effective, can carry a risk of skin cancer with repeated exposure.
Systemic immunosuppressants are used with some success in patients with dyshidrotic dermatitis that is unresponsive to conventional therapy, and for recalcitrant disease unresponsive to phototherapy.[43]Egan CA, Rallis TM, Meadows KP, et al. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Derm. 1999;40:612-614.
http://www.ncbi.nlm.nih.gov/pubmed/10188683?tool=bestpractice.com
[44]Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol. 1999;455:343-348.
http://www.ncbi.nlm.nih.gov/pubmed/10599368?tool=bestpractice.com
[45]Granlund H, Erkko P, Eriksson E, et al. Comparison of cyclosporine and topical betamethasone-17, 21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol. 1996;76:371-376.
http://www.ncbi.nlm.nih.gov/pubmed/8891011?tool=bestpractice.com
[46]Pickenäcker A, Luger TA, Schwartz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol. 1998;134:378-379.
http://www.ncbi.nlm.nih.gov/pubmed/9521043?tool=bestpractice.com
However, evidence of efficacy for dyshidrotic dermatitis is weak.[39]Christoffers WA, Coenraads PJ, Svensson Å, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019 Apr 26;4(4):CD004055.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004055.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/31025714?tool=bestpractice.com